nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitaxentan—EDNRB—melanoma	0.72	1	CbGaD
Sitaxentan—CYP3A4—Temozolomide—melanoma	0.0275	0.576	CbGbCtD
Sitaxentan—CYP3A4—Vemurafenib—melanoma	0.0151	0.316	CbGbCtD
Sitaxentan—CYP3A4—Docetaxel—melanoma	0.00517	0.108	CbGbCtD
Sitaxentan—Haemoglobin—Bleomycin—melanoma	0.000234	0.00169	CcSEcCtD
Sitaxentan—Constipation—Vemurafenib—melanoma	0.000234	0.00169	CcSEcCtD
Sitaxentan—Pancytopenia—Temozolomide—melanoma	0.000233	0.00168	CcSEcCtD
Sitaxentan—Haemorrhage—Bleomycin—melanoma	0.000233	0.00168	CcSEcCtD
Sitaxentan—Dysuria—Temozolomide—melanoma	0.00023	0.00166	CcSEcCtD
Sitaxentan—Hyperglycaemia—Carmustine—melanoma	0.000229	0.00165	CcSEcCtD
Sitaxentan—Pollakiuria—Temozolomide—melanoma	0.000227	0.00164	CcSEcCtD
Sitaxentan—Photosensitivity reaction—Temozolomide—melanoma	0.000224	0.00162	CcSEcCtD
Sitaxentan—Renal failure—Carmustine—melanoma	0.000223	0.00161	CcSEcCtD
Sitaxentan—Weight decreased—Temozolomide—melanoma	0.000222	0.0016	CcSEcCtD
Sitaxentan—Hyperglycaemia—Temozolomide—melanoma	0.000222	0.0016	CcSEcCtD
Sitaxentan—Stomatitis—Carmustine—melanoma	0.000221	0.00159	CcSEcCtD
Sitaxentan—Infestation NOS—Temozolomide—melanoma	0.000219	0.00158	CcSEcCtD
Sitaxentan—Infestation—Temozolomide—melanoma	0.000219	0.00158	CcSEcCtD
Sitaxentan—Hepatitis—Dactinomycin—melanoma	0.000218	0.00157	CcSEcCtD
Sitaxentan—Flushing—Bleomycin—melanoma	0.000216	0.00156	CcSEcCtD
Sitaxentan—Body temperature increased—Vemurafenib—melanoma	0.000216	0.00156	CcSEcCtD
Sitaxentan—Stomatitis—Temozolomide—melanoma	0.000214	0.00154	CcSEcCtD
Sitaxentan—Deafness—Docetaxel—melanoma	0.000211	0.00152	CcSEcCtD
Sitaxentan—Hepatic failure—Docetaxel—melanoma	0.00021	0.00152	CcSEcCtD
Sitaxentan—Cardiac failure congestive—Docetaxel—melanoma	0.000209	0.0015	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Temozolomide—melanoma	0.000207	0.00149	CcSEcCtD
Sitaxentan—Alopecia—Bleomycin—melanoma	0.000206	0.00149	CcSEcCtD
Sitaxentan—Sinusitis—Temozolomide—melanoma	0.000206	0.00148	CcSEcCtD
Sitaxentan—Haemoglobin—Carmustine—melanoma	0.000205	0.00148	CcSEcCtD
Sitaxentan—Haemorrhage—Carmustine—melanoma	0.000204	0.00147	CcSEcCtD
Sitaxentan—Flushing—Dactinomycin—melanoma	0.000202	0.00146	CcSEcCtD
Sitaxentan—Hypersensitivity—Vemurafenib—melanoma	0.000202	0.00145	CcSEcCtD
Sitaxentan—Oedema peripheral—Carmustine—melanoma	0.000201	0.00145	CcSEcCtD
Sitaxentan—Menopausal symptoms—Docetaxel—melanoma	0.0002	0.00144	CcSEcCtD
Sitaxentan—Visual disturbance—Docetaxel—melanoma	0.0002	0.00144	CcSEcCtD
Sitaxentan—Renal impairment—Docetaxel—melanoma	0.000199	0.00143	CcSEcCtD
Sitaxentan—Haemoglobin—Temozolomide—melanoma	0.000198	0.00143	CcSEcCtD
Sitaxentan—Hepatitis—Temozolomide—melanoma	0.000197	0.00142	CcSEcCtD
Sitaxentan—Haemorrhage—Temozolomide—melanoma	0.000197	0.00142	CcSEcCtD
Sitaxentan—Asthenia—Vemurafenib—melanoma	0.000196	0.00141	CcSEcCtD
Sitaxentan—Visual impairment—Carmustine—melanoma	0.000196	0.00141	CcSEcCtD
Sitaxentan—Urinary tract disorder—Temozolomide—melanoma	0.000194	0.0014	CcSEcCtD
Sitaxentan—Oedema peripheral—Temozolomide—melanoma	0.000194	0.0014	CcSEcCtD
Sitaxentan—Cardiac failure—Docetaxel—melanoma	0.000194	0.0014	CcSEcCtD
Sitaxentan—Urethral disorder—Temozolomide—melanoma	0.000193	0.00139	CcSEcCtD
Sitaxentan—Alopecia—Dactinomycin—melanoma	0.000192	0.00139	CcSEcCtD
Sitaxentan—Eye disorder—Carmustine—melanoma	0.00019	0.00137	CcSEcCtD
Sitaxentan—Visual impairment—Temozolomide—melanoma	0.00019	0.00137	CcSEcCtD
Sitaxentan—Gastrointestinal haemorrhage—Docetaxel—melanoma	0.000189	0.00136	CcSEcCtD
Sitaxentan—Flushing—Carmustine—melanoma	0.000189	0.00136	CcSEcCtD
Sitaxentan—Ill-defined disorder—Bleomycin—melanoma	0.000188	0.00136	CcSEcCtD
Sitaxentan—Anaemia—Bleomycin—melanoma	0.000188	0.00135	CcSEcCtD
Sitaxentan—Diarrhoea—Vemurafenib—melanoma	0.000187	0.00135	CcSEcCtD
Sitaxentan—Migraine—Docetaxel—melanoma	0.000186	0.00134	CcSEcCtD
Sitaxentan—Eye disorder—Temozolomide—melanoma	0.000184	0.00133	CcSEcCtD
Sitaxentan—Tinnitus—Temozolomide—melanoma	0.000183	0.00132	CcSEcCtD
Sitaxentan—Malaise—Bleomycin—melanoma	0.000183	0.00132	CcSEcCtD
Sitaxentan—Flushing—Temozolomide—melanoma	0.000183	0.00132	CcSEcCtD
Sitaxentan—Cardiac disorder—Temozolomide—melanoma	0.000183	0.00132	CcSEcCtD
Sitaxentan—Leukopenia—Bleomycin—melanoma	0.000182	0.00131	CcSEcCtD
Sitaxentan—Dizziness—Vemurafenib—melanoma	0.000181	0.0013	CcSEcCtD
Sitaxentan—Alopecia—Carmustine—melanoma	0.00018	0.0013	CcSEcCtD
Sitaxentan—Angiopathy—Temozolomide—melanoma	0.000179	0.00129	CcSEcCtD
Sitaxentan—Mental disorder—Carmustine—melanoma	0.000178	0.00129	CcSEcCtD
Sitaxentan—Ataxia—Docetaxel—melanoma	0.000178	0.00128	CcSEcCtD
Sitaxentan—Immune system disorder—Temozolomide—melanoma	0.000178	0.00128	CcSEcCtD
Sitaxentan—Mediastinal disorder—Temozolomide—melanoma	0.000177	0.00128	CcSEcCtD
Sitaxentan—Malnutrition—Carmustine—melanoma	0.000177	0.00128	CcSEcCtD
Sitaxentan—Dehydration—Docetaxel—melanoma	0.000176	0.00127	CcSEcCtD
Sitaxentan—Ill-defined disorder—Dactinomycin—melanoma	0.000176	0.00127	CcSEcCtD
Sitaxentan—Anaemia—Dactinomycin—melanoma	0.000175	0.00126	CcSEcCtD
Sitaxentan—Liver function test abnormal—Docetaxel—melanoma	0.000175	0.00126	CcSEcCtD
Sitaxentan—Vomiting—Vemurafenib—melanoma	0.000174	0.00125	CcSEcCtD
Sitaxentan—Alopecia—Temozolomide—melanoma	0.000174	0.00125	CcSEcCtD
Sitaxentan—Dry skin—Docetaxel—melanoma	0.000173	0.00125	CcSEcCtD
Sitaxentan—Chest pain—Bleomycin—melanoma	0.000173	0.00125	CcSEcCtD
Sitaxentan—Abdominal pain upper—Docetaxel—melanoma	0.000173	0.00125	CcSEcCtD
Sitaxentan—Orthostatic hypotension—Docetaxel—melanoma	0.000173	0.00125	CcSEcCtD
Sitaxentan—Rash—Vemurafenib—melanoma	0.000172	0.00124	CcSEcCtD
Sitaxentan—Mental disorder—Temozolomide—melanoma	0.000172	0.00124	CcSEcCtD
Sitaxentan—Dermatitis—Vemurafenib—melanoma	0.000172	0.00124	CcSEcCtD
Sitaxentan—Headache—Vemurafenib—melanoma	0.000171	0.00124	CcSEcCtD
Sitaxentan—Malnutrition—Temozolomide—melanoma	0.000171	0.00123	CcSEcCtD
Sitaxentan—Breast disorder—Docetaxel—melanoma	0.000171	0.00123	CcSEcCtD
Sitaxentan—Discomfort—Bleomycin—melanoma	0.000171	0.00123	CcSEcCtD
Sitaxentan—Malaise—Dactinomycin—melanoma	0.000171	0.00123	CcSEcCtD
Sitaxentan—Cramp muscle—Docetaxel—melanoma	0.00017	0.00123	CcSEcCtD
Sitaxentan—Aspartate aminotransferase increased—Docetaxel—melanoma	0.00017	0.00123	CcSEcCtD
Sitaxentan—Leukopenia—Dactinomycin—melanoma	0.00017	0.00122	CcSEcCtD
Sitaxentan—Confusional state—Bleomycin—melanoma	0.000167	0.0012	CcSEcCtD
Sitaxentan—Alanine aminotransferase increased—Docetaxel—melanoma	0.000167	0.0012	CcSEcCtD
Sitaxentan—Tremor—Carmustine—melanoma	0.000166	0.0012	CcSEcCtD
Sitaxentan—Oedema—Bleomycin—melanoma	0.000166	0.00119	CcSEcCtD
Sitaxentan—Infection—Bleomycin—melanoma	0.000165	0.00119	CcSEcCtD
Sitaxentan—Anaemia—Carmustine—melanoma	0.000164	0.00118	CcSEcCtD
Sitaxentan—Agitation—Carmustine—melanoma	0.000163	0.00117	CcSEcCtD
Sitaxentan—Nausea—Vemurafenib—melanoma	0.000162	0.00117	CcSEcCtD
Sitaxentan—Thrombocytopenia—Bleomycin—melanoma	0.000162	0.00117	CcSEcCtD
Sitaxentan—Tremor—Temozolomide—melanoma	0.00016	0.00116	CcSEcCtD
Sitaxentan—Discomfort—Dactinomycin—melanoma	0.000159	0.00115	CcSEcCtD
Sitaxentan—Angina pectoris—Docetaxel—melanoma	0.000159	0.00115	CcSEcCtD
Sitaxentan—Ill-defined disorder—Temozolomide—melanoma	0.000159	0.00115	CcSEcCtD
Sitaxentan—Leukopenia—Carmustine—melanoma	0.000159	0.00114	CcSEcCtD
Sitaxentan—Anaemia—Temozolomide—melanoma	0.000158	0.00114	CcSEcCtD
Sitaxentan—Anorexia—Bleomycin—melanoma	0.000158	0.00114	CcSEcCtD
Sitaxentan—Agitation—Temozolomide—melanoma	0.000157	0.00113	CcSEcCtD
Sitaxentan—Pancytopenia—Docetaxel—melanoma	0.000155	0.00112	CcSEcCtD
Sitaxentan—Hypotension—Bleomycin—melanoma	0.000155	0.00112	CcSEcCtD
Sitaxentan—Oedema—Dactinomycin—melanoma	0.000155	0.00111	CcSEcCtD
Sitaxentan—Malaise—Temozolomide—melanoma	0.000154	0.00111	CcSEcCtD
Sitaxentan—Vertigo—Temozolomide—melanoma	0.000154	0.00111	CcSEcCtD
Sitaxentan—Infection—Dactinomycin—melanoma	0.000154	0.00111	CcSEcCtD
Sitaxentan—Leukopenia—Temozolomide—melanoma	0.000153	0.00111	CcSEcCtD
Sitaxentan—Thrombocytopenia—Dactinomycin—melanoma	0.000151	0.00109	CcSEcCtD
Sitaxentan—Chest pain—Carmustine—melanoma	0.000151	0.00109	CcSEcCtD
Sitaxentan—Weight decreased—Docetaxel—melanoma	0.000148	0.00107	CcSEcCtD
Sitaxentan—Anorexia—Dactinomycin—melanoma	0.000147	0.00106	CcSEcCtD
Sitaxentan—Confusional state—Carmustine—melanoma	0.000146	0.00105	CcSEcCtD
Sitaxentan—Infestation NOS—Docetaxel—melanoma	0.000146	0.00105	CcSEcCtD
Sitaxentan—Infestation—Docetaxel—melanoma	0.000146	0.00105	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000145	0.00104	CcSEcCtD
Sitaxentan—Oedema—Carmustine—melanoma	0.000145	0.00104	CcSEcCtD
Sitaxentan—Discomfort—Temozolomide—melanoma	0.000144	0.00104	CcSEcCtD
Sitaxentan—Decreased appetite—Bleomycin—melanoma	0.000144	0.00104	CcSEcCtD
Sitaxentan—Infection—Carmustine—melanoma	0.000144	0.00104	CcSEcCtD
Sitaxentan—Acute coronary syndrome—Docetaxel—melanoma	0.000144	0.00104	CcSEcCtD
Sitaxentan—Renal failure—Docetaxel—melanoma	0.000143	0.00103	CcSEcCtD
Sitaxentan—Myocardial infarction—Docetaxel—melanoma	0.000143	0.00103	CcSEcCtD
Sitaxentan—Dry mouth—Temozolomide—melanoma	0.000143	0.00103	CcSEcCtD
Sitaxentan—Stomatitis—Docetaxel—melanoma	0.000142	0.00102	CcSEcCtD
Sitaxentan—Jaundice—Docetaxel—melanoma	0.000142	0.00102	CcSEcCtD
Sitaxentan—Pain—Bleomycin—melanoma	0.000142	0.00102	CcSEcCtD
Sitaxentan—Conjunctivitis—Docetaxel—melanoma	0.000142	0.00102	CcSEcCtD
Sitaxentan—Thrombocytopenia—Carmustine—melanoma	0.000142	0.00102	CcSEcCtD
Sitaxentan—Tachycardia—Carmustine—melanoma	0.000141	0.00102	CcSEcCtD
Sitaxentan—Confusional state—Temozolomide—melanoma	0.000141	0.00102	CcSEcCtD
Sitaxentan—Oedema—Temozolomide—melanoma	0.00014	0.00101	CcSEcCtD
Sitaxentan—Infection—Temozolomide—melanoma	0.000139	0.001	CcSEcCtD
Sitaxentan—Anorexia—Carmustine—melanoma	0.000138	0.000994	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Docetaxel—melanoma	0.000138	0.000994	CcSEcCtD
Sitaxentan—Epistaxis—Docetaxel—melanoma	0.000137	0.000991	CcSEcCtD
Sitaxentan—Nervous system disorder—Temozolomide—melanoma	0.000137	0.000988	CcSEcCtD
Sitaxentan—Thrombocytopenia—Temozolomide—melanoma	0.000137	0.000987	CcSEcCtD
Sitaxentan—Feeling abnormal—Bleomycin—melanoma	0.000137	0.000984	CcSEcCtD
Sitaxentan—Skin disorder—Temozolomide—melanoma	0.000136	0.000979	CcSEcCtD
Sitaxentan—Hypotension—Carmustine—melanoma	0.000135	0.000974	CcSEcCtD
Sitaxentan—Decreased appetite—Dactinomycin—melanoma	0.000134	0.000968	CcSEcCtD
Sitaxentan—Fatigue—Dactinomycin—melanoma	0.000133	0.000961	CcSEcCtD
Sitaxentan—Anorexia—Temozolomide—melanoma	0.000133	0.000961	CcSEcCtD
Sitaxentan—Pain—Dactinomycin—melanoma	0.000132	0.000953	CcSEcCtD
Sitaxentan—Urticaria—Bleomycin—melanoma	0.000132	0.000949	CcSEcCtD
Sitaxentan—Haemoglobin—Docetaxel—melanoma	0.000132	0.000948	CcSEcCtD
Sitaxentan—Rhinitis—Docetaxel—melanoma	0.000131	0.000946	CcSEcCtD
Sitaxentan—Body temperature increased—Bleomycin—melanoma	0.000131	0.000944	CcSEcCtD
Sitaxentan—Hepatitis—Docetaxel—melanoma	0.000131	0.000943	CcSEcCtD
Sitaxentan—Haemorrhage—Docetaxel—melanoma	0.000131	0.000943	CcSEcCtD
Sitaxentan—Insomnia—Carmustine—melanoma	0.000131	0.000943	CcSEcCtD
Sitaxentan—Urinary tract disorder—Docetaxel—melanoma	0.000129	0.000931	CcSEcCtD
Sitaxentan—Oedema peripheral—Docetaxel—melanoma	0.000129	0.000929	CcSEcCtD
Sitaxentan—Somnolence—Carmustine—melanoma	0.000129	0.000927	CcSEcCtD
Sitaxentan—Urethral disorder—Docetaxel—melanoma	0.000128	0.000925	CcSEcCtD
Sitaxentan—Feeling abnormal—Dactinomycin—melanoma	0.000127	0.000918	CcSEcCtD
Sitaxentan—Insomnia—Temozolomide—melanoma	0.000126	0.000911	CcSEcCtD
Sitaxentan—Visual impairment—Docetaxel—melanoma	0.000126	0.000909	CcSEcCtD
Sitaxentan—Decreased appetite—Carmustine—melanoma	0.000126	0.000906	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Carmustine—melanoma	0.000125	0.0009	CcSEcCtD
Sitaxentan—Somnolence—Temozolomide—melanoma	0.000124	0.000896	CcSEcCtD
Sitaxentan—Pain—Carmustine—melanoma	0.000124	0.000892	CcSEcCtD
Sitaxentan—Constipation—Carmustine—melanoma	0.000124	0.000892	CcSEcCtD
Sitaxentan—Dyspepsia—Temozolomide—melanoma	0.000123	0.000887	CcSEcCtD
Sitaxentan—Eye disorder—Docetaxel—melanoma	0.000122	0.000881	CcSEcCtD
Sitaxentan—Body temperature increased—Dactinomycin—melanoma	0.000122	0.000881	CcSEcCtD
Sitaxentan—Hypersensitivity—Bleomycin—melanoma	0.000122	0.00088	CcSEcCtD
Sitaxentan—Decreased appetite—Temozolomide—melanoma	0.000122	0.000876	CcSEcCtD
Sitaxentan—Flushing—Docetaxel—melanoma	0.000121	0.000875	CcSEcCtD
Sitaxentan—Cardiac disorder—Docetaxel—melanoma	0.000121	0.000875	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Temozolomide—melanoma	0.000121	0.00087	CcSEcCtD
Sitaxentan—Fatigue—Temozolomide—melanoma	0.000121	0.000869	CcSEcCtD
Sitaxentan—Pain—Temozolomide—melanoma	0.00012	0.000862	CcSEcCtD
Sitaxentan—Constipation—Temozolomide—melanoma	0.00012	0.000862	CcSEcCtD
Sitaxentan—Feeling abnormal—Carmustine—melanoma	0.000119	0.000859	CcSEcCtD
Sitaxentan—Asthenia—Bleomycin—melanoma	0.000119	0.000857	CcSEcCtD
Sitaxentan—Angiopathy—Docetaxel—melanoma	0.000119	0.000856	CcSEcCtD
Sitaxentan—Immune system disorder—Docetaxel—melanoma	0.000118	0.000852	CcSEcCtD
Sitaxentan—Mediastinal disorder—Docetaxel—melanoma	0.000118	0.00085	CcSEcCtD
Sitaxentan—Alopecia—Docetaxel—melanoma	0.000116	0.000833	CcSEcCtD
Sitaxentan—Feeling abnormal—Temozolomide—melanoma	0.000115	0.00083	CcSEcCtD
Sitaxentan—Mental disorder—Docetaxel—melanoma	0.000115	0.000826	CcSEcCtD
Sitaxentan—Body temperature increased—Carmustine—melanoma	0.000114	0.000824	CcSEcCtD
Sitaxentan—Malnutrition—Docetaxel—melanoma	0.000114	0.000821	CcSEcCtD
Sitaxentan—Hypersensitivity—Dactinomycin—melanoma	0.000114	0.000821	CcSEcCtD
Sitaxentan—Urticaria—Temozolomide—melanoma	0.000111	0.000801	CcSEcCtD
Sitaxentan—Asthenia—Dactinomycin—melanoma	0.000111	0.000799	CcSEcCtD
Sitaxentan—Body temperature increased—Temozolomide—melanoma	0.000111	0.000797	CcSEcCtD
Sitaxentan—Muscle spasms—Docetaxel—melanoma	0.00011	0.000789	CcSEcCtD
Sitaxentan—Hypersensitivity—Carmustine—melanoma	0.000107	0.000768	CcSEcCtD
Sitaxentan—Diarrhoea—Dactinomycin—melanoma	0.000106	0.000762	CcSEcCtD
Sitaxentan—Vomiting—Bleomycin—melanoma	0.000105	0.00076	CcSEcCtD
Sitaxentan—Anaemia—Docetaxel—melanoma	0.000105	0.000759	CcSEcCtD
Sitaxentan—Rash—Bleomycin—melanoma	0.000104	0.000753	CcSEcCtD
Sitaxentan—Dermatitis—Bleomycin—melanoma	0.000104	0.000753	CcSEcCtD
Sitaxentan—Asthenia—Carmustine—melanoma	0.000104	0.000748	CcSEcCtD
Sitaxentan—Hypersensitivity—Temozolomide—melanoma	0.000103	0.000742	CcSEcCtD
Sitaxentan—Leukopenia—Docetaxel—melanoma	0.000102	0.000735	CcSEcCtD
Sitaxentan—Asthenia—Temozolomide—melanoma	0.0001	0.000723	CcSEcCtD
Sitaxentan—Diarrhoea—Carmustine—melanoma	9.9e-05	0.000713	CcSEcCtD
Sitaxentan—Nausea—Bleomycin—melanoma	9.84e-05	0.00071	CcSEcCtD
Sitaxentan—Vomiting—Dactinomycin—melanoma	9.83e-05	0.000708	CcSEcCtD
Sitaxentan—Rash—Dactinomycin—melanoma	9.75e-05	0.000702	CcSEcCtD
Sitaxentan—Chest pain—Docetaxel—melanoma	9.7e-05	0.000699	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	9.63e-05	0.000694	CcSEcCtD
Sitaxentan—Dizziness—Carmustine—melanoma	9.57e-05	0.00069	CcSEcCtD
Sitaxentan—Diarrhoea—Temozolomide—melanoma	9.56e-05	0.000689	CcSEcCtD
Sitaxentan—Dry mouth—Docetaxel—melanoma	9.48e-05	0.000684	CcSEcCtD
Sitaxentan—Confusional state—Docetaxel—melanoma	9.37e-05	0.000676	CcSEcCtD
Sitaxentan—Oedema—Docetaxel—melanoma	9.3e-05	0.00067	CcSEcCtD
Sitaxentan—Dizziness—Temozolomide—melanoma	9.24e-05	0.000666	CcSEcCtD
Sitaxentan—Infection—Docetaxel—melanoma	9.24e-05	0.000666	CcSEcCtD
Sitaxentan—Vomiting—Carmustine—melanoma	9.2e-05	0.000663	CcSEcCtD
Sitaxentan—Nausea—Dactinomycin—melanoma	9.18e-05	0.000662	CcSEcCtD
Sitaxentan—Rash—Carmustine—melanoma	9.12e-05	0.000657	CcSEcCtD
Sitaxentan—Nervous system disorder—Docetaxel—melanoma	9.12e-05	0.000657	CcSEcCtD
Sitaxentan—Dermatitis—Carmustine—melanoma	9.11e-05	0.000657	CcSEcCtD
Sitaxentan—Thrombocytopenia—Docetaxel—melanoma	9.1e-05	0.000656	CcSEcCtD
Sitaxentan—Tachycardia—Docetaxel—melanoma	9.07e-05	0.000654	CcSEcCtD
Sitaxentan—Headache—Carmustine—melanoma	9.06e-05	0.000653	CcSEcCtD
Sitaxentan—Skin disorder—Docetaxel—melanoma	9.03e-05	0.000651	CcSEcCtD
Sitaxentan—Vomiting—Temozolomide—melanoma	8.89e-05	0.000641	CcSEcCtD
Sitaxentan—Anorexia—Docetaxel—melanoma	8.86e-05	0.000639	CcSEcCtD
Sitaxentan—Rash—Temozolomide—melanoma	8.81e-05	0.000635	CcSEcCtD
Sitaxentan—Dermatitis—Temozolomide—melanoma	8.81e-05	0.000635	CcSEcCtD
Sitaxentan—Headache—Temozolomide—melanoma	8.76e-05	0.000631	CcSEcCtD
Sitaxentan—Hypotension—Docetaxel—melanoma	8.69e-05	0.000626	CcSEcCtD
Sitaxentan—Nausea—Carmustine—melanoma	8.59e-05	0.000619	CcSEcCtD
Sitaxentan—Insomnia—Docetaxel—melanoma	8.41e-05	0.000606	CcSEcCtD
Sitaxentan—Nausea—Temozolomide—melanoma	8.3e-05	0.000599	CcSEcCtD
Sitaxentan—Somnolence—Docetaxel—melanoma	8.26e-05	0.000596	CcSEcCtD
Sitaxentan—Dyspepsia—Docetaxel—melanoma	8.18e-05	0.00059	CcSEcCtD
Sitaxentan—Decreased appetite—Docetaxel—melanoma	8.08e-05	0.000583	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Docetaxel—melanoma	8.03e-05	0.000579	CcSEcCtD
Sitaxentan—Fatigue—Docetaxel—melanoma	8.02e-05	0.000578	CcSEcCtD
Sitaxentan—Constipation—Docetaxel—melanoma	7.95e-05	0.000573	CcSEcCtD
Sitaxentan—Pain—Docetaxel—melanoma	7.95e-05	0.000573	CcSEcCtD
Sitaxentan—Feeling abnormal—Docetaxel—melanoma	7.66e-05	0.000552	CcSEcCtD
Sitaxentan—Body temperature increased—Docetaxel—melanoma	7.35e-05	0.00053	CcSEcCtD
Sitaxentan—Hypersensitivity—Docetaxel—melanoma	6.85e-05	0.000494	CcSEcCtD
Sitaxentan—Asthenia—Docetaxel—melanoma	6.67e-05	0.000481	CcSEcCtD
Sitaxentan—Diarrhoea—Docetaxel—melanoma	6.36e-05	0.000459	CcSEcCtD
Sitaxentan—Dizziness—Docetaxel—melanoma	6.15e-05	0.000443	CcSEcCtD
Sitaxentan—Vomiting—Docetaxel—melanoma	5.91e-05	0.000426	CcSEcCtD
Sitaxentan—Rash—Docetaxel—melanoma	5.86e-05	0.000423	CcSEcCtD
Sitaxentan—Dermatitis—Docetaxel—melanoma	5.86e-05	0.000422	CcSEcCtD
Sitaxentan—Headache—Docetaxel—melanoma	5.82e-05	0.00042	CcSEcCtD
Sitaxentan—Nausea—Docetaxel—melanoma	5.52e-05	0.000398	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—KDR—melanoma	2.52e-05	0.000268	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—SOCS1—melanoma	2.5e-05	0.000265	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—MAP2K1—melanoma	2.49e-05	0.000265	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—S100B—melanoma	2.49e-05	0.000265	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—PIK3CD—melanoma	2.47e-05	0.000263	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—FN1—melanoma	2.43e-05	0.000258	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—HS3ST5—melanoma	2.39e-05	0.000254	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—ERBB4—melanoma	2.38e-05	0.000253	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—NOTCH1—melanoma	2.38e-05	0.000252	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—PIK3CB—melanoma	2.37e-05	0.000252	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CDKN2B—melanoma	2.36e-05	0.000251	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CD80—melanoma	2.33e-05	0.000247	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—KIT—melanoma	2.32e-05	0.000247	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—APC—melanoma	2.32e-05	0.000247	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PIK3CG—melanoma	2.32e-05	0.000247	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—NRAS—melanoma	2.32e-05	0.000247	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—EGF—melanoma	2.3e-05	0.000244	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CD86—melanoma	2.28e-05	0.000243	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—CXCL8—melanoma	2.28e-05	0.000243	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—EDN1—melanoma	2.27e-05	0.000241	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—MAPK3—melanoma	2.22e-05	0.000236	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CSF2—melanoma	2.21e-05	0.000235	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—FGF1—melanoma	2.21e-05	0.000235	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—BRAF—melanoma	2.18e-05	0.000232	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—IL2—melanoma	2.18e-05	0.000232	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—E2F1—melanoma	2.17e-05	0.00023	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—PIK3CB—melanoma	2.16e-05	0.000229	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PDGFRA—melanoma	2.14e-05	0.000228	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IGF1—melanoma	2.13e-05	0.000226	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—ITGB3—melanoma	2.12e-05	0.000226	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PRKCA—melanoma	2.12e-05	0.000226	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—MAPK1—melanoma	2.12e-05	0.000225	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—EGFR—melanoma	2.12e-05	0.000225	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CYP17A1—melanoma	2.11e-05	0.000224	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—SPP1—melanoma	2.08e-05	0.000221	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MAP2K2—melanoma	2.08e-05	0.000221	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CXCL8—melanoma	2.07e-05	0.00022	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MAP2K1—melanoma	2.06e-05	0.000218	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PIK3CD—melanoma	2.04e-05	0.000217	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—PIK3CA—melanoma	2.02e-05	0.000215	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—KRAS—melanoma	2e-05	0.000212	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PLCB4—melanoma	1.99e-05	0.000211	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—IL2—melanoma	1.98e-05	0.00021	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TERT—melanoma	1.97e-05	0.00021	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—RAC1—melanoma	1.97e-05	0.000209	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—FGF2—melanoma	1.96e-05	0.000208	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—FASN—melanoma	1.95e-05	0.000207	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP17A1—melanoma	1.92e-05	0.000204	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—HIF1A—melanoma	1.89e-05	0.000201	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PIP4K2A—melanoma	1.87e-05	0.000198	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—SLC6A11—melanoma	1.87e-05	0.000198	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ACER3—melanoma	1.85e-05	0.000197	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—PIK3CA—melanoma	1.84e-05	0.000195	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MDM2—melanoma	1.83e-05	0.000194	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—MTAP—melanoma	1.82e-05	0.000193	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PLCB4—melanoma	1.81e-05	0.000192	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—KDR—melanoma	1.8e-05	0.000192	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—ERBB2—melanoma	1.8e-05	0.000192	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PIK3CB—melanoma	1.78e-05	0.000189	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—FASN—melanoma	1.78e-05	0.000189	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—melanoma	1.77e-05	0.000189	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—FN1—melanoma	1.74e-05	0.000185	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CXCL8—melanoma	1.71e-05	0.000182	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PIP4K2A—melanoma	1.7e-05	0.000181	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—SLC6A11—melanoma	1.7e-05	0.000181	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—NOTCH1—melanoma	1.7e-05	0.000181	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—HRAS—melanoma	1.7e-05	0.000181	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—UGT2B10—melanoma	1.69e-05	0.00018	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CDKN1B—melanoma	1.67e-05	0.000178	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CD80—melanoma	1.67e-05	0.000177	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—KIT—melanoma	1.66e-05	0.000177	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PIK3CG—melanoma	1.66e-05	0.000177	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—APC—melanoma	1.66e-05	0.000177	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—NRAS—melanoma	1.66e-05	0.000177	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—MTAP—melanoma	1.66e-05	0.000176	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—AKT1—melanoma	1.65e-05	0.000176	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—EGF—melanoma	1.64e-05	0.000175	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CASP3—melanoma	1.64e-05	0.000174	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IL2—melanoma	1.63e-05	0.000174	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—IL6—melanoma	1.63e-05	0.000173	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PHGDH—melanoma	1.62e-05	0.000172	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—LUM—melanoma	1.62e-05	0.000172	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—melanoma	1.62e-05	0.000172	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CCND1—melanoma	1.59e-05	0.000169	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—MAPK3—melanoma	1.59e-05	0.000169	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—HPSE—melanoma	1.59e-05	0.000169	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CTNNB1—melanoma	1.58e-05	0.000168	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—HS3ST5—melanoma	1.58e-05	0.000167	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—BRAF—melanoma	1.56e-05	0.000166	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CUBN—melanoma	1.56e-05	0.000166	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MMP9—melanoma	1.55e-05	0.000164	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CDKN1A—melanoma	1.54e-05	0.000164	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PTEN—melanoma	1.54e-05	0.000163	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—NFKB1—melanoma	1.53e-05	0.000163	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IGF1—melanoma	1.52e-05	0.000162	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—MAPK1—melanoma	1.52e-05	0.000161	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—EGFR—melanoma	1.51e-05	0.000161	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—SDHD—melanoma	1.5e-05	0.00016	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—BSG—melanoma	1.5e-05	0.00016	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CSPG4—melanoma	1.5e-05	0.00016	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—AKT1—melanoma	1.5e-05	0.000159	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PHGDH—melanoma	1.48e-05	0.000157	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—LUM—melanoma	1.48e-05	0.000157	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MAP2K1—melanoma	1.47e-05	0.000156	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PIK3CD—melanoma	1.46e-05	0.000155	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GPAM—melanoma	1.46e-05	0.000155	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—PIK3CA—melanoma	1.45e-05	0.000154	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—HPSE—melanoma	1.45e-05	0.000154	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—KRAS—melanoma	1.43e-05	0.000152	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CUBN—melanoma	1.42e-05	0.000151	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—FGF2—melanoma	1.4e-05	0.000149	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—VEGFA—melanoma	1.39e-05	0.000148	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—STAT3—melanoma	1.38e-05	0.000146	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—NRAS—melanoma	1.37e-05	0.000146	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CSPG4—melanoma	1.37e-05	0.000146	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—BSG—melanoma	1.37e-05	0.000146	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—SDHD—melanoma	1.37e-05	0.000146	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GPAM—melanoma	1.33e-05	0.000141	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—PIK3CA—melanoma	1.31e-05	0.00014	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MAPK3—melanoma	1.31e-05	0.00014	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MDM2—melanoma	1.31e-05	0.000139	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—ERBB2—melanoma	1.29e-05	0.000137	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MYC—melanoma	1.28e-05	0.000136	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PIK3CB—melanoma	1.27e-05	0.000135	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MAPK1—melanoma	1.25e-05	0.000133	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—EGFR—melanoma	1.25e-05	0.000133	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PLA2G6—melanoma	1.24e-05	0.000132	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CXCL8—melanoma	1.22e-05	0.00013	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—HRAS—melanoma	1.22e-05	0.000129	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CDKN1B—melanoma	1.2e-05	0.000127	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PLCB4—melanoma	1.19e-05	0.000127	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—AKT1—melanoma	1.18e-05	0.000126	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—KRAS—melanoma	1.18e-05	0.000126	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CASP3—melanoma	1.17e-05	0.000125	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IL2—melanoma	1.17e-05	0.000124	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—IL6—melanoma	1.16e-05	0.000124	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CCND1—melanoma	1.14e-05	0.000121	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PLA2G6—melanoma	1.13e-05	0.00012	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CTNNB1—melanoma	1.13e-05	0.00012	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SLC6A11—melanoma	1.12e-05	0.000119	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PIP4K2A—melanoma	1.12e-05	0.000119	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—VCAN—melanoma	1.11e-05	0.000118	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MMP9—melanoma	1.11e-05	0.000118	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CDKN1A—melanoma	1.1e-05	0.000117	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PTEN—melanoma	1.1e-05	0.000117	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—NFKB1—melanoma	1.1e-05	0.000116	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—MTAP—melanoma	1.09e-05	0.000116	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PIK3CA—melanoma	1.09e-05	0.000115	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—AKT1—melanoma	1.07e-05	0.000114	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	1.05e-05	0.000112	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TP53—melanoma	1.05e-05	0.000112	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—melanoma	1.02e-05	0.000108	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—VCAN—melanoma	1.01e-05	0.000108	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—HRAS—melanoma	1e-05	0.000107	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—VEGFA—melanoma	9.94e-06	0.000106	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—STAT3—melanoma	9.85e-06	0.000105	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—NRAS—melanoma	9.82e-06	0.000104	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PHGDH—melanoma	9.73e-06	0.000103	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—LUM—melanoma	9.73e-06	0.000103	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IL6—melanoma	9.61e-06	0.000102	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	9.61e-06	0.000102	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—HPSE—melanoma	9.54e-06	0.000101	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MAPK3—melanoma	9.41e-06	0.0001	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYP17A1—melanoma	9.39e-06	9.98e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CUBN—melanoma	9.37e-06	9.96e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—melanoma	9.27e-06	9.85e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	9.26e-06	9.84e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MYC—melanoma	9.15e-06	9.72e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—ALB—melanoma	9.14e-06	9.72e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SDHD—melanoma	9.05e-06	9.62e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CSPG4—melanoma	9.05e-06	9.62e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—BSG—melanoma	9.05e-06	9.62e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MAPK1—melanoma	8.95e-06	9.51e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—EGFR—melanoma	8.95e-06	9.51e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GNA11—melanoma	8.87e-06	9.42e-05	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—AKT1—melanoma	8.86e-06	9.42e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GPAM—melanoma	8.76e-06	9.31e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—FASN—melanoma	8.68e-06	9.22e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYP17A1—melanoma	8.56e-06	9.1e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—SLC5A5—melanoma	8.54e-06	9.07e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—KRAS—melanoma	8.45e-06	8.98e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	8.44e-06	8.97e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—melanoma	8.34e-06	8.86e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GNAQ—melanoma	8.24e-06	8.76e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CD44—melanoma	8.24e-06	8.76e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GNA11—melanoma	8.09e-06	8.59e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	8.07e-06	8.58e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—melanoma	8e-06	8.5e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—FASN—melanoma	7.91e-06	8.41e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYP1B1—melanoma	7.9e-06	8.4e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—SLC5A5—melanoma	7.78e-06	8.27e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PIK3CA—melanoma	7.77e-06	8.25e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GNAQ—melanoma	7.52e-06	7.99e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CD44—melanoma	7.52e-06	7.99e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TP53—melanoma	7.51e-06	7.98e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PLA2G6—melanoma	7.45e-06	7.92e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	7.36e-06	7.82e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—melanoma	7.29e-06	7.75e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYP1B1—melanoma	7.21e-06	7.66e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—HRAS—melanoma	7.19e-06	7.64e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—melanoma	6.98e-06	7.41e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IL6—melanoma	6.88e-06	7.31e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—VCAN—melanoma	6.69e-06	7.11e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ABCB1—melanoma	6.51e-06	6.92e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—melanoma	6.36e-06	6.76e-05	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—AKT1—melanoma	6.34e-06	6.74e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PRKCA—melanoma	5.99e-06	6.37e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ERCC2—melanoma	5.94e-06	6.31e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ABCB1—melanoma	5.93e-06	6.31e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYP17A1—melanoma	5.65e-06	6e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PRKCA—melanoma	5.46e-06	5.8e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ERCC2—melanoma	5.42e-06	5.76e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GNA11—melanoma	5.33e-06	5.67e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—FASN—melanoma	5.22e-06	5.55e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SLC5A5—melanoma	5.13e-06	5.46e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GNAQ—melanoma	4.96e-06	5.27e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CD44—melanoma	4.96e-06	5.27e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	4.92e-06	5.23e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYP1B1—melanoma	4.75e-06	5.05e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PIK3CG—melanoma	4.69e-06	4.99e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PPARG—melanoma	4.53e-06	4.81e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	4.49e-06	4.77e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PIK3CG—melanoma	4.28e-06	4.55e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PPARG—melanoma	4.13e-06	4.39e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PIK3CD—melanoma	4.12e-06	4.38e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ALB—melanoma	4.07e-06	4.33e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ABCB1—melanoma	3.91e-06	4.16e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PIK3CD—melanoma	3.76e-06	4e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ALB—melanoma	3.71e-06	3.95e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PRKCA—melanoma	3.6e-06	3.83e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PIK3CB—melanoma	3.59e-06	3.82e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ERCC2—melanoma	3.57e-06	3.8e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PTGS2—melanoma	3.56e-06	3.79e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PIK3CB—melanoma	3.28e-06	3.48e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PTGS2—melanoma	3.25e-06	3.45e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PTEN—melanoma	3.11e-06	3.3e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PTEN—melanoma	2.83e-06	3.01e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PIK3CG—melanoma	2.82e-06	3e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PPARG—melanoma	2.72e-06	2.89e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PIK3CD—melanoma	2.48e-06	2.64e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ALB—melanoma	2.45e-06	2.6e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PIK3CA—melanoma	2.19e-06	2.33e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PIK3CB—melanoma	2.16e-06	2.3e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PTGS2—melanoma	2.14e-06	2.28e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PIK3CA—melanoma	2e-06	2.12e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PTEN—melanoma	1.87e-06	1.99e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—AKT1—melanoma	1.79e-06	1.9e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—AKT1—melanoma	1.63e-06	1.73e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PIK3CA—melanoma	1.32e-06	1.4e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—AKT1—melanoma	1.08e-06	1.14e-05	CbGpPWpGaD
